BCL2 and acute myeloid leukemia: By integrating genetic, pharmacological, transcriptomic, and genomic approaches, we identified the transcription factor ZNF740 as a crucial regulator of venetoclax sensitivity and uncover a potential ZNF740-NOXA-MCL-1 axis that governs the cellular response to BCL-2 inhibition in AML.